Breast Cancer

Houston, TX

139 Breast Cancer Trials near Houston, TX

Power is an online platform that helps thousands of Breast Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Fulvestrant + Abemaciclib for Breast Cancer

Houston, Texas
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

28 Participants Needed

Chemotherapy Response Prediction for Breast Cancer

Houston, Texas
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

185 Participants Needed

T-DM1 vs TH for Breast Cancer

Houston, Texas
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

500 Participants Needed

Tucatinib + Trastuzumab Deruxtecan for Breast Cancer

Houston, Texas
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

70 Participants Needed

Margetuximab vs Trastuzumab Combinations for Breast Cancer

Houston, Texas
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

174 Participants Needed

FDG-PET/CT Assessment for Breast Cancer

Houston, Texas
This trial studies how well certain scans work in assessing the response of patients with breast cancer that has spread to the bones. The scans use a special substance to highlight active cancer areas on detailed body images, helping doctors see if the treatment is working. These scans have been used successfully for various stages and evaluations of breast cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

138 Participants Needed

Chemotherapy Reduction After Surgery for Breast Cancer

Houston, Texas
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

2175 Participants Needed

PMD-026 for Breast Cancer

Houston, Texas
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

61 Participants Needed

Talazoparib for Breast Cancer

Houston, Texas
This trial is testing talazoparib, a drug that may help treat breast cancer that has spread and has specific genetic mutations (BRCA 1 or BRCA 2). Talazoparib works by stopping proteins that repair DNA, making it harder for cancer cells to survive. The goal is to see if this drug can reduce tumor size and slow down cancer growth in these patients. Talazoparib is a new treatment recently approved for use in patients with metastatic breast cancer with germline BRCA mutations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female

30 Participants Needed

Carvedilol for Cardiomyopathy in Breast Cancer Patients

Houston, Texas
Breast cancer patients undergoing trastuzumab-based HER2-directed therapy are at risk of heart function decline or heart failure symptoms, but it is unknown if, when, and for how long cardiovascular protective strategies, e.g. with a beta-blocker, could help. This study randomly assigns those taking curative-intent trastuzumab-based HER2-directed therapy to the beta-blocker carvedilol-either when significant heart function decline or subtle early signs of heart injury (either by elevation of a cardiac blood biomarker, i.e. cardiac troponin, or by an abnormal heart ultrasound marker, i.e. global longitudinal strain) are noted, or preventatively before beginning trastuzumab-based HER2-directed therapy. This study will further randomly assign those patients on carvedilol to either discontinuation at the end of trastuzumab-based HER2-directed therapy or continuation for another year, providing much needed clinical trial data on what the best strategy ("tactic") for those at risk of cardiotoxicity with trastuzumab-based HER2-directed therapy is.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

184 Participants Needed

Durvalumab + Trastuzumab + Pertuzumab for Breast Cancer

Houston, Texas
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female

39 Participants Needed

Immunotherapy + Radiation for Hormone-Sensitive Breast Cancer

Houston, Texas
This trial tests different treatments in post-menopausal women with a specific type of breast cancer. The goal is to find the best way to lower hormones, kill cancer cells, or boost the immune system to fight the disease. One of the treatments being tested is a medication used for treating postmenopausal women with hormone-sensitive advanced breast cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female

100 Participants Needed

Radiation Therapy + Olaparib for Breast Cancer

Houston, Texas
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

300 Participants Needed

Simvastatin + Anti-HER2 Therapy for Breast Cancer

Houston, Texas
This trial tests if adding simvastatin, a cholesterol-lowering drug, to the current treatment can help patients with advanced breast cancer that has spread and is not responding to usual treatments. The goal is to see if this combination can make the cancer treatment work better. Simvastatin, originally used to lower cholesterol, has been studied since the 1990s for its potential anticancer effects, including in breast cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female

5 Participants Needed

Combination Therapy for Breast Cancer

Houston, Texas
This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: * Fulvestrant * Fulvestrant with Palbociclib * Fulvestrant with Palbociclib and Avelumab
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

220 Participants Needed

Estrogen vs Moisturizer for Vaginal Dryness in Breast Cancer Patients

Houston, Texas
This trial compares a hormone-releasing ring and a moisturizing cream for treating vaginal dryness in breast cancer patients. It focuses on post-menopausal women undergoing specific cancer treatments who suffer from vaginal dryness. The hormone ring works by adding estrogen locally, while the cream provides moisture without hormones.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female

44 Participants Needed

HKI-272 for Breast Cancer

Houston, Texas
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

140 Participants Needed

AVZO-023 for Breast Cancer

Houston, Texas
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

380 Participants Needed

RYZ101 Alone and with Pembrolizumab for Breast Cancer

Houston, Texas
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

124 Participants Needed

[177Lu]Lu-NeoB + Capecitabine for Metastatic Breast Cancer

Houston, Texas
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[177Lu\]Lu-NeoB in combination with capecitabine (dose optimization).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

58 Participants Needed

Why Other Patients Applied

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

UM
Pancreatic Cancer PatientAge: 48

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

PF-07220060 + Fulvestrant for Advanced Breast Cancer

Houston, Texas
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

333 Participants Needed

STX-478 + Fulvestrant for Advanced Breast Cancer

Houston, Texas
This trial is testing a new drug called STX-478 to see if it can help treat advanced solid tumors and breast cancer. The study will look at how safe the drug is, how it behaves in the body, and if it can stop or slow down cancer growth. Some patients will receive just STX-478, while others will get it combined with another drug called fulvestrant, which is often used to treat advanced breast cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

720 Participants Needed

Combination Therapy for Advanced Breast Cancer

Houston, Texas
This trial tests a combination of an oral cancer drug, an IV chemotherapy drug, and another IV drug in patients with a rare, hard-to-treat type of breast cancer. The goal is to improve treatment response by blocking cancer growth signals and resistance pathways. The study targets patients whose cancer has not responded to other treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

36 Participants Needed

Endoxifen for Breast Cancer

Houston, Texas
This trial is testing (Z)-endoxifen, a drug that blocks estrogen, in pre-menopausal women with a specific type of breast cancer. The study aims to see if this drug can slow down cancer growth by measuring a marker called Ki-67. Participants will take the drug daily for several months before surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female

214 Participants Needed

ARV-471 + Ribociclib for Advanced Breast Cancer

Houston, Texas
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: * is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy * is sensitive to hormonal therapy (it is called estrogen receptor positive); and * is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study B: All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and ribociclib will be given at the same time by mouth, at home, 1 time a day. The experiences of people receiving the study medicine will be examined. This will help determine if the study medicine is safe and effective. Participants will continue to take ARV-471 and ribociclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

20 Participants Needed

Elacestrant Combinations for Breast Cancer

Houston, Texas
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

435 Participants Needed

ARV-471 + Abemaciclib for Advanced Breast Cancer

Houston, Texas
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: * is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy * is sensitive to hormonal therapy (it is called estrogen receptor positive); and * is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study A: All participants will receive ARV-471 and a medicine called abemaciclib. ARV-471 will be given by mouth, at home, 1 time a day. Abemaciclib will be given by mouth, at home, 2 times a day. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective. Participants will continue to take ARV-471 and abemaciclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

37 Participants Needed

Hormone Therapy for Male Breast Cancer

Houston, Texas
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male

60 Participants Needed

ARX788 for HER2-Positive Breast Cancer

Houston, Texas
This trial tests ARX788, a new IV medicine, for patients with HER2-positive metastatic breast cancer who did not respond well to T-DXd. The medicine targets a specific protein on cancer cells to help stop their growth.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

71 Participants Needed

BT8009 + Pembrolizumab for Solid Tumors

Houston, Texas
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C), and characterization of the pharmacokinetics (Part D).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

329 Participants Needed

12345

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Breast Cancer clinical trials in Houston, TX pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Breast Cancer clinical trials in Houston, TX work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Breast Cancer trials in Houston, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Houston, TX for Breast Cancer is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Houston, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Breast Cancer medical study in Houston, TX?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Breast Cancer clinical trials in Houston, TX?

Most recently, we added Cyclophosphamide + Axatilimab + Retifanlimab for Breast Cancer, Adjuvant Radiotherapy for Breast Cancer and Izalontamab Brengitecan for Breast Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Texas

Anxiety Clinical Trials in Texas

Schizophrenia Clinical Trials in Texas

ADHD Clinical Trials in Texas

Bipolar Disorder Clinical Trials in Texas

Multiple Sclerosis Clinical Trials in Texas

Autism Clinical Trials in Texas

Treatment Resistant Depression Clinical Trials in Texas

Borderline Personality Disorder Clinical Trials in Texas

Social Anxiety Disorder Clinical Trials in Texas

Parkinson's Disease Clinical Trials in Texas

Alzheimer's Disease Clinical Trials in Texas

By Location

Clinical Trials near Houston, TX

Clinical Trials near Dallas, TX

Clinical Trials near San Antonio, TX

Clinical Trials near Austin, TX

Clinical Trials near Fort Worth, TX

Clinical Trials near Plano, TX

Clinical Trials near Tyler, TX

Clinical Trials near El Paso, TX

Clinical Trials near Lubbock, TX

Clinical Trials near Galveston, TX

Clinical Trials near Temple, TX

Clinical Trials near Arlington, TX

Other People Viewed

By Subject

Top Lung Cancer Clinical Trials near Houston, TX

Top Colorectal Cancer Clinical Trials near Houston, TX

152 Breast Cancer Trials near San Antonio, TX

Top Clinical Trials near Houston, TX

Top Clinical Trials near Houston, TX

Top Breast Cancer Clinical Trials near Dallas, TX

Top Depression Clinical Trials near Houston, TX

Top Prostate Cancer Clinical Trials near Houston, TX

Top Diabetes Clinical Trials near Houston, TX

Top Clinical Trials near Fort Sam Houston, TX

Top Arthritis Clinical Trials near Houston, TX

Top Breast Cancer Clinical Trials near Ventura, CA

By Trial

Exercise for Breast Cancer Survivors

Contrast-Enhanced Mammography for Breast Cancer

Scalp Cooling for Breast Cancer

Trastuzumab Deruxtecan for Breast Cancer

Ribociclib + Belinostat for Breast Cancer

Patient-Centered Communication Interventions for Breast Cancer

Nanoparticle Chemotherapy for Breast Cancer

Metformin + Fasting for Breast Cancer

Epidiferphane + Taxane Chemotherapy for Breast Cancer

T-DXd +/− Pertuzumab for Breast Cancer

Tamoxifen vs. TamGel for Breast Cancer Risk Reduction

Sacituzumab Govitecan + Pembrolizumab for Breast Cancer

Related Searches

Top Breast-cancer Clinical Trials near Cincinnati, OH

Top Breast-cancer Clinical Trials near Tampa, FL

Top Breast-cancer Clinical Trials near Miami, FL

Top Breast-cancer Clinical Trials near Philadelphia, PA

Top Breast-cancer Clinical Trials near Phoenix, AZ

Top Breast-cancer Clinical Trials near Raleigh, NC

Ritlecitinib for Cutaneous T-Cell Lymphoma

Dipyridamole for Low Phosphate

Avocado for Post-Meal Blood Sugar Control

cCeLL Imaging for Brain Cancer

Single-Day vs Longitudinal NRP Training for Neonatal Resuscitation Skills

Zanzalintinib + Etoposide for Germ Cell Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial